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Background: Accumulating evidence suggests that some long noncoding RNAs (lncRNAs) are involved in certain
diseases, such as cancer. The lncRNA, CCDC26, is related to childhood acute myeloid leukemia (AML) because its
copy number is altered in AML patients.
Results: We found that CCDC26 transcripts were abundant in the nuclear fraction of K562 human myeloid leukemia
cells. To examine the function of CCDC26, gene knockdown (KD) was performed using short hairpin RNAs (shRNAs),
and four KD clones, in which CCDC26 expression was suppressed to 1% of its normal level, were isolated. This
down-regulation included suppression of CCDC26 intron-containing transcripts (the CCDC26 precursor mRNA), indicating
that transcriptional gene suppression (TGS), not post-transcriptional suppression, was occurring. The shRNA targeting one
of the two CCDC26 splice variants also suppressed the other splice variant, which is further evidence for TGS. Growth rates
of KD clones were reduced compared with non-KD control cells in media containing normal or high serum
concentrations. In contrast, enhanced growth rates in media containing much lower serum concentrations
and increased survival periods after serum withdrawal were observed for KD clones. DNA microarray and
quantitative polymerase chain reaction screening for differentially expressed genes between KD clones and
non-KD control cells revealed significant up-regulation of the tyrosine kinase receptor, KIT, hyperactive
mutations of which are often found in AML. Treatment of KD clones with ISCK03, a KIT-specific inhibitor,
eliminated the increased survival of KD clones in the absence of serum.
Conclusions: We suggest that CCDC26 controls growth of myeloid leukemia cells through regulation of KIT
expression. A KIT inhibitor might be an effective treatment against the forms of AML in which CCDC26 is
altered.
Keywords: Long noncoding RNA, Myeloid leukemia cells, Cell survival, Receptor tyrosine kinase,
shRNA-induced transcriptional gene suppression, Stem cell factor, Serum depletionBackground
Noncoding RNAs (ncRNAs) are usually transcribed by
RNA polymerase II and have intrinsic functions without
being translated into polypeptides [1-4]. MicroRNAs
(miRNAs), are important ncRNAs of approximately
20 bp that silence specific target genes [5-9], while long
noncoding RNAs (lncRNAs) are between 200 bp and
several kb and have numerous roles in cellular functions* Correspondence: thirano@hiroshima-u.ac.jp
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unless otherwise stated.and gene regulation [10]. However, apart from a few
examples, the molecular mechanisms by which most
lncRNAs function remain to be fully elucidated [11,12].
Accumulating evidence suggests that some lncRNAs are
involved in diseases, such as cancer [13,14]; therefore, it
is important to understand their roles to facilitate the
search for new therapeutic targets and to design new
diagnostic methods.
Acute myeloid leukemia (AML) is a disease characterized
by mutations in a set of genes [15-17]. These genes can be
divided into two classes. One class includes genes related
to cell differentiation, HOXA9, AML1, MLL and RARα, and
the other consists of genes related to proliferation orThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Mutations in genes of both classes need to occur to give
rise to AML [15,18]. Fusion of BCR and ABL (BCR/ABL) is
well known to be sufficient to cause chronic myeloid
leukemia (CML) [19]. However, acute blastic crisis of CML
is often accompanied by mutation of genes that are also
mutated in AML, such as HOXA9 or AML1 [20,21]. Thus,
hematopoietic tyrosine kinases, including FLT3, ABL, RAS
and KIT, seem to have a similar role in AML and CML
[22]. Considering the importance of imatinib, an ABL tyro-
sine kinase inhibitor used in the treatment of BCR/ABL-
positive CML, inhibitors against other tyrosine kinases are
likely to become increasingly important for the treatment
of AML [19,23]. KIT is a receptor tyrosine kinase that is
considered to have a role in AML because of its frequent
up-regulation in patients. Expression of KIT in leukemia
stem cells (LSCs) from pediatric AML patients who re-
lapsed after chemotherapy was increased compared with
that in patients who did not relapse [24].
The function of the lncRNA, CCDC26, is not known.
There is no evidence for a functional CCDC26 protein;
moreover, the hypothetical 109 amino acid protein
encoded in its mRNA has no homology with known pro-
teins [25]. Despite the ambiguous nature of CCDC26,
several lines of evidence support a relationship of
CCDC26 with tumors, including AML. Radtke and col-
leagues investigated copy number alterations (CNAs) in
pediatric AML genomes and found that the most com-
mon CNA is a low burden increase of a region within
the CCDC26 locus [26]. Studies by ourselves and others
have shown that part of or the entire CCDC26 gene is
often amplified in AML cells harboring aberrant double
minute chromosomes [27-29]. Others suggest that sensi-
tivity of AML cells to anticancer drugs, including retin-
oic acid, is lost with integration of retroviral DNA into
the CCDC26 locus [30]. Linkage of CCDC26 with tu-
mors, including low-grade glioma, was also suggested by
genome wide association studies [31].
In this paper, we demonstrate that knockdown of
CCDC26 in CML-derived K562 cells results in
transcriptionally-altered expression of several genes, in-
cluding activation of KIT, and prolonged cell survival
under low or no serum conditions. ISCK03, a KIT in-
hibitor, abolished this prolonged survival. These results
provide evidence for a new role of CCDC26 in myeloid
leukemia through the regulation of a set of genes that
includes KIT.
Results
Expression of CCDC26 in various leukemia cell lines
To investigate the spectrum of cells that express
CCDC26, the absolute number of RNA molecules in a
cell was determined by quantitative polymerase chain
reaction (PCR) in several representative leukemia andnon-leukemia cancer cell lines. The results are summa-
rized in Figure 1A. CCDC26 was expressed in cells derived
from AML (HL-60, ML-1, 039/TSU, KG-1, GDM-1,
SKNO-1), acute monocytic leukemia (THP-1) and CML
(K562, Meg-01, KU-812, MYLR). Very low expression
(estimated at one molecule per cell, taking into account
loss of RNA during preparation from cells) was ob-
served in megakaryoblastic cells derived from leukemia
accompanied with Down’s syndrome (CMK) and in
monocytic leukemia cells derived from histiocytic
lymphoma (U937). No expression was observed in T
lymphocytic leukemia cells (Jurkat), Burkitt’s lymph-
oma cells (Raji) or nonhematopoietic cells, including
U251MG (astrocytoma) and HeLa (cervical cancer)
cells. These data indicate that expression of CCDC26 is
strictly limited to myeloid cell lines of hematopoietic
origin. Among them, the strongest expression of
CCDC26 was observed in the AML cell line, HL-60.
HL-60 cells, however, have a recombination upstream
of CCDC26 exon 4 and exons 1 to 3 of the gene are
amplified on a double minute chromosome, which is an
aberrant ring structure consisting of at least six discon-
tinuous regions spanning 440 Mb of 8q24. This region
contains several genes, including CCDC26 and MYC,
and several abnormal transcripts, one of which involves
CCDC26 exons fused to other unrelated sequences,
have been detected [27]. To avoid influence from such
a complicated abnormal structure, we choose the K562
cell line, not HL-60, for further detailed analysis be-
cause CCDC26 is also strongly expressed in this cell
line and has no rearrangement in the vicinity of the
CCDC26 locus on 8q24.
Different transcripts are generated from the CCDC26
locus
K562 is a representative hematopoietic cell line, for
which extensive biological information is archived in the
Encyclopedia of DNA elements database [32]. According
to information in the database, there are several tran-
scriptional hot sites in CCDC26, including THS1 and
THS2, as indicated in Figure 1B, where transcripts accu-
mulate within introns outside of the known exons. In
addition, there is a region designated hAK015428 show-
ing a significant level of transcript in the 5′ region
upstream of the first exon (Figure 1B). This region is
conserved with the mouse ncRNA, AK015428 (Genbank
accession number: AK015428). Indeed, we observed sig-
nificant numbers of THS1, THS2 and hAK015428 tran-
scripts (Figure 1C). hAK015428 was concentrated in the
polyA+ fraction and its transcription was in the same
direction as that of CCDC26; therefore, it seems to be
an independent lncRNA (Additional file 1: Figure S1A
and our unpublished data). We observed accumulation
of CCDC26 and hAK015428 transcripts in isolated
Figure 1 (See legend on next page.)
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Figure 1 Expression of CCDC26 ncRNA. A: Estimated absolute number of CCDC26 mRNA molecules per cell in representative hematopoietic and
nonhematopoietic cell lines, shown in the log scale. The absolute number of mRNA molecules per K562 cell of HPRT1, a house keeping gene, and
BCR/ABL, an oncogene expressed in K562 cells, was measured as 21+/−5 and 45+/14, respectively. B: A map of human chromosome 8q24,
showing the location of the CCDC26 mRNA long and short variants (Genbank accession numbers: NR_130918 and NR_130917, respectively), other
minor variants (NR_130919 and NR_130920) containing exon 2A, transcripts including hAK015428, transcriptional hot site 1 (THS1) and THS2, and
scores of nuclear and whole cell transcripts in K562 cells. These scores are reprinted from the Human Feb. 2009 (GRCh37/hg19) assembly of the
UCSC Genome Browser (http://genome.ucsc.edu/). C: Estimated absolute number of CCDC26, intron THS1, THS2 and hAK015428 transcripts in a
K562 cell. D: Quantification of RNA in isolated nuclei and whole cells by quantitative PCR. For each assay, the same amount of RNA was used to
synthesize cDNA. The value for HPRT in whole cell RNA was used as a standard. SNORA74, a snoRNA strictly located in nuclei, was used as a
control for purity of the nuclear fraction.
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Figure S1A), suggesting a nuclear function.
Repression of CCDC26 with short-hairpin knockdown
vectors
The function of CCDC26 was studied by constitutive
knockdown using pGER, a short hairpin RNA (shRNA)
expression plasmid (Additional file 2: Figure S2A) modi-
fied from GeneEraser pGE-1. We designed two shRNAs
(sh-1250-1278 and sh-1440-1468) to knock down both
the long and short variants of CCDC26 and two add-
itional shRNAs (sh-331-359 and sh-279-307) to target
only the long variant (Figure 2A). Figure 2B shows the
results of screening clones for shRNA suppression of
CCDC26 (details of results for all clones are shown in
Additional file 2: Figure S2B). Although CCDC26 sup-
pression failed in most isolated clones, CCDC26 was
suppressed in five clones (22B11, 32H8, 3–4, 3D1 and
32E3) to levels of less than 2% of that in nontransfected
K562 cells. After a second screen, we chose four clones
(22B11, 32H8, 3–4 and 3D1) for further analysis in
which expression of CCDC26 was repressed to levels of
less than 1% of that in control cells (Figure 3C). Clone
32E3 was omitted because the level of CCDC26 expres-
sion was greater than 1% of that in control cells.
Transcriptional silencing of CCDC26 in knockdown clones
Only one of the two transcript variants (the long variant)
was targeted in clones 3–4 and 3D1; however, we observed
total knockdown of all CCDC26 expression. To confirm
this observation, we used additional primer sets and we
detected that each CCDC26 mRNA variant was knocked
down with similar efficiency. As shown in Figure 1B, there
are transcriptionally active sites in CCDC26 introns.
We tested expression from these sites and found that
they were also silenced, except for THS2 in knockdown
(KD) clone 32H8 (Figure 3B). We also tested the expres-
sion of several genes in the vicinity of the CCDC26 locus
(chromosome 8 location; 128,750,000–130,800,000)
(Figure 3A). We found efficient silencing of
LOC728724, a gene independent from CCDC26, in all
KD clones and partial silencing of GSDMC in clones
3–4 and 3D1. However, PVT1 and MYC were notsignificantly repressed (Figure 3B). Suppression of
GSDMC in clones 3–4 and 3D1 was partially prevented by
treatment with 1.0 μM trichostatin A (TSA), an inhibitor
of histone deacetylase, and 1.0 μM 5-aza-2′-deoxycytidine
(AzdC), an inhibitor of DNA methyltransferase (DNMT)
(Figure 3C), indicating that the silencing of these genes
was mediated, at least in part, by epigenetic mechanisms.
In contrast, suppression of CCDC26 was not prevented by
treatment with TSA and AzdC (Figure 3C).
CCDC26 knockdown cells grow slowly in high
concentrations of serum and show prolonged survival
under serum depletion
Proliferation of K562 cell lines in medium containing
15% fetal bovine serum (FBS) and 0.1% FBS was mea-
sured by counting live cells, as determined by trypan
blue exclusion. Nontransformed and vector-transformed
K562 cells proliferate rapidly with a doubling time of less
than 12 hours, whereas KD clones showed prolonged
doubling times (approximately 20 hours) (Figure 4A). In
media containing 5–10% FBS, similar differences in
growth rate between non-KD and KD cells were ob-
served (data not shown). However, more live KD cells
were observed compared with non-KD cells after culture
for 72 hours under serum starvation conditions (0.1%
FBS) (Figure 4B). We detected no significant morpho-
logical differences or altered expression of β-globin (a
differentiation state marker for K562 cells) between KD
clones and non-KD clones indicating no significant dif-
ference in the differentiation state of the clones (data
not shown).
Less than 10% of non-KD and KD cells died when
grown in medium containing high (5% or more) concen-
trations of FBS up to a density of 1.5 × 106 cells/ml (data
not shown). In contrast, a high number of dead cells was
observed under low serum conditions after serum star-
vation for 72 hours or more. Dead cells, as assessed by
propidium iodide (PI) uptake, were counted by flow cy-
tometry (FACS) analysis (Figure 4C–F). Significantly
fewer dead cells were observed in KD clones compared
with non-KD clones at 72 and 96 hours after serum de-
pletion (Figure 4C and E). Figure 4D and F show FACS
analysis examples of cells 72 and 96 hours after serum
Figure 2 Knockdown of CCDC26 with shRNAs. A. Sequences of shRNAs used in this work. The stems formed in hairpin structures are indicated
with bold type. The heads of hairpin structures are indicated by underlined sequence. B. First screen of CCDC26 suppression with shRNA vectors.
Clones 22B11, 32H8, 3–4 and 3D1 were used in further investigations (bold type). Clone 32E3 was omitted after a second screening. Targets of
the shRNAs are mapped on exon structures (1-2-3-4 and 1a-3-4) of the CCDC26 mRNA variants (see Figure 1B). C. Expression of CCDC26 exon 3–4
in four clones, 3–4, 22B11, 3D1 and 32H8, selected after the second screening. All values were normalized to the expression of CCDC26 in
K562 cells.
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creased with time after serum depletion for all cell lines;
however, the cell death rate in KD clones was lower than
that in control cells at 96 as well as 72 hours after serum
depletion. The right major peak (labeled “DEAD”) corre-
sponding to PI-stained dead cells consists of overlapping
double peaks of cells in G1 (open arrow) and G2/M
phases (closed arrow). The number of dead cells in the
G2/M phase was preferentially decreased in KD cells.
This indicates suppression of cell death at a certain point
in the cell cycle in KD cells. This result was confirmed
by cell-cycle assessment of separated dead and live cellspermeabilized and stained with PI. Essentially no differ-
ence in distribution of cell cycle-phase was observed
between KD and non-KD cells in separated live cells,
whereas there was a significant shift in distribution from
G1 to S/G2/M in dead cells (Additional file 3: Figure
S3A). The rate of cell death for cells grown in 0.1% FBS-
or non-FBS-containing medium was also measured by
staining with trypan blue. Under each condition, essen-
tially the same result was obtained as above; less cell
death was observed in KD clones compared with that in
non-KD cells after serum starvation for 72 hours or
more (Additional file 3: Figure S3B).
AB
C
Figure 3 (See legend on next page.)
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Figure 3 Silencing of the CCDC26 locus in KD clones. A: A map of chromosomal region 8q24 in the vicinity of CCDC26 (128,800,000–130,800,000;
sequence numbering is according to the human genome assembly, GRCh37/hg19). Exon-intron structures are not shown. Arrows indicate the
direction of transcription. Location and gene annotation are summarized in the table below. B: Expression of CCDC26-short, CCDC26-long,
LOC728724, GSDMC, THS1, THS2, human AK015428 homolog (hAK015428), PVTC1 and MYC. Graphs are shown in the log2 scale. C: Treatment with
trichostatin A (TSA) and 5-aza-2′-deoxycytidine (AzdC) prevented the suppression of GSDMC but not CCDC26. Open and filled boxes indicate with
or without TSA + AzdC, respectively.
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between CCDC26-KD and non-KD cells
To comprehensively investigate differences of gene ex-
pression between KD and non-KD cells, we carried out
DNA microarray analysis with RNA purified from non-
transfected K562 cells, vector-transformed cells, and KD
clones, 3–4 and 22B11 (Figure 5A). Detailed raw results
are presented in Additional file 4: Table S1. We ex-
tracted 117 genes that showed a 2-fold or greater change
in expression level in both KD clones compared with the
control cells (Figure 5B and Additional file 5: Table S2).
A heat map to visualize their expression is shown in
Additional file 6: Figure S4A. Up- or down-regulation of
109 out of 117 genes was detected in both KD cell lines,
indicating a consistency of altered gene expression in
CCDC26-KD cells (P = 1.24E-20, chi-square test for the
categorical data in Figure 5C). We chose several most
highly differentially expressed candidates for further in-
vestigation in the additional KD clones, 3D1 and 32H8,
and identified KIT, CD24 and PASD1 to be significantly
activated in all KD clones compared with non-KD clones
(Figure 5D upper panel). At the same time, MS4A3,
SAMSN1 and MS4A4 were suppressed in all KD clones
(Figure 5D lower panel). Among the six activated and
suppressed genes, KIT was the strongest candidate to
be a target of CCDC26 because KIT is known to be fre-
quently mutated in AML [23]. Moreover, pathway ana-
lysis revealed that KIT, CD24 and MS4A4 form
regulatory linkages involving other genes as mediators
(Additional file 6: Figure S4B) with KIT having a central
role in the regulatory network (Additional file 7: Table
S3). For confirmation, we quantified other genes fre-
quently altered in AML, including TET2, IDH1, IDH2,
DNMT3A, ASXL1, EZH-2, MLL, RUNX, CBFB and
TCF3 [33], but we observed no consistent activation or
repression of any of these genes in KD cells (Additional
file 8: Figure S5).
Differential KIT protein levels between CCDC26-KD and
non-KD cells
The abundance of KIT protein was confirmed by west-
ern blot analysis (Figure 6A). The major band of 145 kD,
corresponding to the membrane bound form of KIT,
was observed in all cell lines. The amount of KIT pro-
tein was increased in all KD cells compared with that in
non-KD cells, in which a weak KIT signal was observed.Further evidence for enhanced KIT levels was obtained
by immunocytochemistry (Figure 6B). In 3–4 and 22B11
KD cells, KIT was concentrated at the plasma mem-
brane and diffusely distributed in the cytoplasm. No
signal was detected in nuclei. These observations con-
firmed the normal localization of KIT in KD cells.
ISCK03, a tyrosine kinase inhibitor specific to KIT,
prevents survival of CCDC26-KD cells under low-serum
conditions
To further investigate the influence of KIT on KD cells,
we treated KD cells with ISCK03, a drug that specifically
inhibits KIT activity [34]. All treated cells exhibited sensi-
tivity to ISCK03 in a dose-dependent manner (Figure 7A).
After ISCK03 treatment, the survival of KD cells was sup-
pressed to the same level as that of non-KD cells. Con-
versely, ISCK03 treatment had limited effects on the
growth of control K562 and KD clone 3–4 cells under
high-serum concentration conditions (Figure 7B). Treat-
ment with imatinib, another tyrosine kinase inhibitor
specific to ABL but not to KIT, completely abolished the
growth of both control K562 and KD cells (Figure 7B).
These drugs produced similar growth effects in both con-
trol K562 and KD clone 3–4 cells in 10% FBS-containing
medium.
Discussion
We found several regions in the CCDC26 locus from
which transcripts are produced. These transcripts
may be independently transcribed or processed from
CCDC26 introns that have been spliced out of its pre-
cursor mRNA. The transcripts accumulate in K562 cells
but, at present, it is difficult to determine which prod-
ucts are functional among the mature mRNA and in-
tronic CCDC26 transcripts [35]. However, accumulation
of mature CCDC26 products in the nucleus suggests a
functional role [36,37].
An shRNA usually suppresses its target gene by
post-transcriptional gene suppression (PTGS), which
includes RNA degradation via the RNA-induced silen-
cing complex (RISC). But in some cases, transcrip-
tional gene suppression (TGS) can take place via the
RNA-induced transcriptional silencing complex (RITS)
[38,39]. In this study, shRNA-mediated PTGS does
not account for the suppression of the majority of
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Figure 4 (See legend on next page.)
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Figure 4 CCDC26-KD clones in culture medium containing high or low serum. Growth of CCDC26-KD clones in culture medium containing 15%
(A) or 0.1% FBS (B). The results show the mean of three or four independent experiments. P values for difference between non-KD (K562 and
Vec, GER vector transformed) and KD (22B11, 32H8, 3–4 and 3D1) groups are shown. C: Number of dead cells after serum depletion measured by
PI staining and flow cytometry. The results indicated the average of two independent experiments. P values for differences between non-KD and
KD groups are shown. D: An example of flow cytometry analysis of cells 72 hours after serum depletion.
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cells because the THS1 transcript was not suppressed
in these cells, as shown in Figure 2B. A straightforward
explanation in this case is TGS. Moreover, the chroma-
tin range over which TGS occurs is somewhat different
among the CCDC26-KD clones and 1.0 μM TSA
and 1.0 μM AzdC partially prevented the silencing
(Figure 3C). Release from silencing by TSA and AzdC
was observed at genes located on the borders of the
suppressed chromosomal region. This suggests that
TGS of these genes by epigenetic mechanisms is ac-
companied by repressive chromatin modification in the
CCDC26-KD clones. In contrast, CCDC26 itself and
the adjacent gene, LOC728724, remained silent even
after treatment with TSA and AzdC (Figure 3C), indi-
cating that TGS of these genes occurs via a different
mechanism.
All the KD clones showed lower growth rates than
non-KD control K562 cells. It seems likely that CCDC26
acts as an oncogene to control cell proliferation, either
directly or indirectly. Paradoxically, however, the KD
clones proliferated more rapidly in low serum conditions
compared with non-KD cells. Additionally, the KD
clones survived for longer under conditions of very low
or no serum compared with non-KD control cells, which
died relatively rapidly under these conditions. This ob-
servation indicates that suppression of CCDC26 enables
leukemia cells to survive and proliferate despite a severe
shortage of growth factors.
DNA microarray and quantitative PCR analysis re-
vealed that the expression of several genes was changed
in KD clones. Among them, activation of KIT is espe-
cially interesting because this gene is over-expressed in
many AML patients. Of note, however, activation of
KIT protein in KD cells seemed to be stochastic in
spite of their monoclonal origin (Figure 6B). It is likely
that there are cells that never express CCDC26 and
cells that express more than one molecule, because the
number of CCDC26 transcripts in knockdown cells was
calculated at less than one per cell, but the transcript
was still detected. This might explain the heteroge-
neous expression of KIT protein in KD cells, although
further investigation is needed to resolve this point. Al-
though the existence of KIT-positive cells per se is not
a prognostic factor, point mutations in KIT that cause
enhanced tyrosine kinase activity are frequently accom-
panied by chromosomal translocation t(8;21) in adultAML, which results in poor prognosis [40]. Other genes,
including CD24 (a sialoglycoprotein expressed on mature
granulocytes and B cells), PASD1 (a transcription factor
expressed in diffuse large B-cell lymphoma), MS4A3 (a
hematopoietic cell-specific membrane protein), SAMSN1
(a protein with an SH3 domain and nuclear localization
signals) and MS4A4 (from the same family as MS4A3) are
also interesting because of their involvement with tumors
but their relationships to myeloid leukemia are not clear.
Nevertheless, we cannot exclude the possibility that
CCDC26 regulates cell proliferation or other properties of
cells through some of these genes. Overall, we suggest that
this ncRNA has novel, previously unknown roles in cellu-
lar function. At present, a regulatory function of CCDC26
has been shown in only a single cell line, K562. Despite
our efforts, we have not been successful in suppressing the
CCDC26 transcripts by RNA interference to sufficient
levels in cell lines other than K562 for unknown reasons
so far (unpublished results). Further study with different
approaches including genome editing might be required
to confirm its function.
Although CCDC26 is a low-burden amplified gene
expressed in some leukemia cells, amplification occurs
partially and does not extend across the whole gene in
most cases. This makes it difficult to know whether
partial amplification of the gene results in enhancement
or loss of its original function. KIT is a well-known
oncogene; therefore, if over-expression of the incomplete
CCDC26 RNA masks KIT function, our findings are
consistent with CCDC26 suppressing some oncogene(s).
However, further investigation is required to fully under-
stand this relationship.
LSCs with CD34+ and CD38− surface markers are
considered to be a cause of AML recurrence because
they have the potential to survive in niche sites that
escape the influence of drugs [41]. CCDC26-KD cells
might share some properties with LSCs, including rela-
tively slow growth and the ability to survive under cer-
tain conditions, such as a shortage of growth factors.
Constitutive activation of KIT might contribute to sur-
vival of these cells by an autocrine mechanism involving
stem cell factor, a ligand for KIT [42]. Although LSCs
are usually negative for KIT in de novo AML [43], the
existence of KIT-positive LSCs is related to an increased
tendency of pediatric AML recurrence after chemother-
apy. This can arise from constitutive activation of KIT
protein [44].
Figure 5 (See legend on next page.)
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Figure 5 Identification of differentially expressed genes between KD and non-KD cells. A: Gene expression levels for KD (22B11 and 3–4) vs. non-KD
(Vec: transformed with the empty vector). The six genes in (D) are indicated. B: Genes whose expression differed by 2-fold or more between KD and
non-KD (Vec.) cells. For 3–4 and 22B11 clones, 429 and 106 genes show altered expression, respectively. Among these genes, 117 showed common
differential expression between 3–4 and 22B11 clones. C: A cross table of the 117 genes categorized into up or down regulation in each clone.
D: Expression was enhanced for three genes (KIT, CD24, PASD1) and repressed for three genes (MS4A3, SAMSN1, MS4A4) in CCDC26-KD cells. The values
were normalized against vector-transformed cells and are shown in the log2 scale. Open and filled boxes indicate enhanced and repressed
expression, respectively.
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CCDC26 is thought to transcriptionally regulate a set of
genes as well as many lncRNAs [45,46]. The collapse of
this regulation might alter the properties of myeloid
leukemia, possibly leading to disease progression. Whole
or partial amplification of the CCDC26 locus is associated
with pediatric AML and double minute chromosome-
positive AML [26,29]. Abnormal CCDC26 RNA structure
could modulate the regulation of KIT to induce undesired
enhanced expression. Leukemia characterized by mutation




HL-60 cells are described elsewhere [47,48]. K562 and
other cells were obtained from ATCC. All cells were
maintained in RPMI 1640 medium supplemented with
10% FBS, 100 U/ml penicillin, 100 U/ml streptomycin at
37°C in a humidified incubator with a 5% CO2 atmos-
phere. KD strains derived from K562 were maintained
with 0.8–1.0 mg/ml G418 and cultured for at least
12 hours in fresh medium without G418 prior to use in
experiments. Cells were counted with a hemocytometer
after staining with 0.25% trypan blue. Dead cells were
stained blue and live cells excluded the dye. TSA
(Sigma-Aldrich, St. Louis, MO, USA) was dissolved in
dimethyl sulfoxide (DMSO) at a concentration of 5 mM.
The 5 mM TSA solution was diluted 1/5000 in culture
medium. AzdC (Sigma-Aldrich) was dissolved in water
and added directly to culture medium. Growth of K562
cells was inhibited by 40–60% in media with 1.0 μM
TSA and 1.0 μM AzdC. Equivalent concentrations of
DMSO were added to control cells without TSA and
AzdC.
Plasmids
The shRNA expression vector, pGER, is a derivative of the
pGE-1 GeneEraser plasmid purchased from Stratagene
(La Jolla, CA, USA). The original SV40 virus early gene
promoter of pGE-1 that drives the G418 resistance marker
gene was substituted with the Rous sarcoma virus
(RSV) promoter, which is more suitable for leukemia
cells. In brief, a 580 bp RSV promoter isolated from
pRSV.5(neo) (GenBank: M83237.1) by digestion withHindIII and NdeI was blunt-end ligated to a 2.6 kb frag-
ment purified from pGE-1 partially digested with StuI
and PvuII.
Isolation of KD clones
Transfection to K562 cells was performed using Dimrie-
C (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions using 0.5 μg of plasmid
DNA per 105 cells in 500 μl medium. Cells were plated
in methylcellulose based-matrix (ClonaCell; Stem Cell
Technologies, Vancouver, Canada) on six-well culture
plates to form colonies and were selected with 1.6
mg/ml G418 from 48 hours after transfection. Visible
colonies were isolated using a Pipetman under micro-
scopic observation after selection for 6–8 days. Cells
were transferred to 96-well plates and were main-
tained to proliferate in culture medium containing
1.6 mg/ml G418. For the first screening, 104 cells were
used for RNA preparation. Clones selected in first
screening were subcloned by the limiting dilution
method and propagated. RNA was then prepared for a
second screening. Colonies of empty pGER transfor-
mants were pooled and used as control non-KD cells.
Quantification of RNA
RNA for quantification was prepared using RNAiso Plus
(Takara Bio, Otsu, Japan) according to the manufac-
turer’s instructions. Synthesis of cDNA was performed
using ReverTra Ace qPCR RT Master Mix with gDNA
Remover (Toyobo, Osaka, Japan) according to the man-
ufacturer’s instructions. Quantification of cDNAs using
primer sets specific to each gene or transcript was per-
formed with the LightCycler system (Roche Diagnostics,
Indianapolis, IN, USA). To measure the absolute num-
ber of cDNA molecules, known concentrations of PCR
product were used to generate a calibration curve. Total
RNA in a single cell was estimated at 10 pg (1 mg for
108 cells). In other quantification, we used HPRT gene
expression as an internal standard. Primer sets used in
PCR experiments are listed in Additional file 9: Table S4.
Isolation of nuclei
Isolation of nuclei was performed according to Spector
et al. [49] with slight modification. In brief, 1 × 107 cells
were washed once with PBS(−) and suspended in 0.5 ml
AB
Figure 6 Detecting differential levels of KIT protein. A: Western blot
analysis for KIT protein in K562, Vec (GER vector transformed), 3–4,
22B11, 3D1 and 32H8 cells. Arrow and asterisks indicate 145 kD
membrane bound KIT (arrow), a 120 kD form of KIT (*) and a 100 kD
(**) soluble form of KIT. The same blot reprobed with an antibody
for beta actin as a loading control is shown below.
B: Immunocytochemistry for KIT in K562, Vec and KD clones (3–4
and 22B11). Nuclei are counter-stained with Hoechst 33342 (blue).
KIT protein is stained red. Higher magnifications for 3–4 and 22B11
are also shown. Scale bars, 50 μm.
Hirano et al. Molecular Cancer  (2015) 14:90 Page 12 of 15of buffer A (10 mM Hepes-KOH [pH 8.0], 10 mM KCl,
1.5 mM MgCl2, 1 mM dithiothreitol (DTT), 0.5 mM
phenylmethylsulfonyl fluoride (PMSF), 0.5 U/μl RNase
inhibitor). Cells were incubated on ice for 10 min and
then lysed in a Dounce homogenizer. Crude nuclei were
collected by centrifugation at 1,300 × g for 5 min and re-
suspended in 0.5 ml buffer B (0.25 M sucrose, 10 mMTris–HCl [pH 7.9], 5 mM MgCl2, 1 mM DTT, 0.5 mM
PMSF). Suspended crude nuclei were centrifuged on a
cushion of 0.4 ml buffer C (1.2 M sucrose, 10 mM Tris–
HCl [pH 7.9], 5 mM MgCl2, 0.1% TritonX-100, 1 mM
DTT, 0.5 mM PMSF) at 10,000 × g for 30 min. Precipi-
tated nuclei were resuspended in 0.5 ml buffer B and
again centrifuged on a cushion of 0.4 ml buffer C. All
procedures were carried out at 0–4°C. The precipitated
nuclear fraction was used directly for RNA preparation
using RNAiso plus (Takara Bio).
DNA microarray analysis
Total RNA from each clone was prepared using
RNAeasy (Qiagen, Venlo, Netherlands) according to the
manufacturer’s instructions. Using an Ambion WT Ex-
pression Kit (Ambion, Foster City, CA, USA) and a WT
Terminal Labeling Kit (Affymetrix, Santa Clara, CA,
USA), 250 ng of RNA was converted to biotin-labeled
single stranded cDNA. Fifteen micrograms of single
stranded DNA was hybridized to a Human Gene 1.0 ST
Array (Affymetrix), followed by staining and washing.
Scanning was carried out using a GeneChip Scanner
3000 7G (Affymetrix).
PI-staining and FACS analysis of dead cells
Cells were washed with PBS and stained in buffer con-
taining 3% FBS, 0.05% NaN3 and 2 μg/ml propidium
iodide (Sigma-Aldrich) for 15 min at room temperature
and analyzed on a FACSCalibur flow cytometer (Beckton
Dickinson, Franklin Lakes, NJ, USA).
Western blot analysis
K562 cells, pGER vector-transformed K562 cells (Vec)
and four strains of K562-KD cells were cultured at 37°C
in a 5% CO2 atmosphere until the logarithmic growth
phase. 2 × 106 cells were lysed by sonication in 0.2 ml
Laemmli buffer (125 mM Tris–HCl, pH 6.8, 4% sodium
dodecyl sulfate (SDS), 100 mM dithiothreitol). Ten
microliters of protein extract, equivalent to 1 × 105 cells,
were separated on a SDS polyacrylamide gel electrophor-
esis pre-made 5–20% gradient gel (Wako Pure Chemical
Industries, Osaka, Japan) and then transferred to poly-
vinylidene fluoride membrane (Immobilon-P Transfer
Membrane; Millipore, Billerica, MA, USA). The blot was
blocked in 7% BlockAce (DS Pharma Biomedical, Osaka
Japan) at 4°C for 2 nights to suppress nonspecific signal
and then incubated in CanGetSignal solution 1 (Toyobo)
with 1/1500 diluted mouse monoclonal anti-KIT anti-
body (#Ab-81; Cell Signaling Technology, Danvers, MA,
USA) and mouse monoclonal anti-beta-actin antibody
(#E1C605; Enogene, New York, NY, USA) (to determine
loading). After washing, the blot was incubated in
CanGetSignal solution 2 (Toyobo) with anti-mouse
IgG secondary antibody conjugated with horseradish
Figure 7 KIT inhibitor prevents survival of CCDC26-KD cells under low serum conditionC A: Effect of a tyrosine kinase inhibitor, ISCK03, on the
proliferation of K562, Vec (GER vector transformed), and KD clones (22B11, 3D1, 32H8 and 3–4). The numbers of cells in culture medium
containing 0.1% FBS with 0 (Veh), 10 μM or 20 μM ISCK03 are shown. *P < 0.05; **P < 0.01 versus corresponding values for Vec. B: Number of
K562 and KD (3–4) cells in culture medium containing 10% FBS with 0 (veh), 10 μM, 20 μM ISCK03 or 0.5 μM imatinib.
Hirano et al. Molecular Cancer  (2015) 14:90 Page 13 of 15peroxidase (KPL, Gaithersburg, MD, USA) and then
visualized with Chemi-lumi One Super (Nakalai Tesque,
Kyoto, Japan). Images were recorded with a Lumino im-
aging analyzer FAS-1000 (Toyobo).
Immunocytochemistry
Cells were suspended and fixed in PBS containing 4%
paraformaldehyde for 15 min at room temperature. After
washing with PBS, cells were suspended in 0.2% Triton/
PBS and incubated for 10 min at room temperature.After washing with PBS, cells were spread on glass slides
using the Thin-layer cell preparation system Cytospin 4
(Thermo-Fisher Scientific, Waltham, MA, USA). Cells
were then incubated with 2% BSA in PBS to block nonspe-
cific signals followed by incubation with 1/100 diluted
mouse monoclonal anti-KIT antibody (#Ab-81; Cell
Signaling Technology) in CanGetSignal immunostain
solution B (Toyobo) overnight at 4°C. Alexa Fluor 546
goat anti-mouse IgG (Invitrogen) was used as a secondary
antibody. The specimens were counterstained with 1 μM
Hirano et al. Molecular Cancer  (2015) 14:90 Page 14 of 15Hoechst 33428 (AnaSpec, Fremont, CA, USA) and
observed under a fluorescence microscope (BA-9000;
Keyence, Osaka, Japan).Additional files
Additional file 1: Figure S1. Summary of expression from the CCDC26
locus. Reprinted from the Human Feb. 2009 (GRCh37/hg19) assembly on
the UCSC Genome Browser. Scores for K562 cells showing whole cell
RNA with polyA, without polyA, cytoplasmic RNA with polyA, without
polyA, nuclear RNA with polyA, without polyA, chromatin associated RNA,
tri-methylated histone H3K4 and acetylation of histone H3K27.
Additional file 2: Figure S2. Summary for CCDC26 knockdown clones.
B: Map of the shRNA vector, pGER. The RSV-promoter (P-RSV) was
inserted in place of the original SV40-promoter to drive expression of the
neo/kan marker gene in pGE-1. B: An example of detailed expression
analysis of KD clones. Values of quantified RNA are shown in the log
scale. Averages of clones (AVR) are shown on the right-hand end of each
graph.
Additional file 3: Figure S3. Cell death of KD cells in low serum
conditions. A: Flow cytometry assessment of cell cycle by PI staining of
separated live and dead cells at 96 hours after serum depletion.
Separation of live and dead cells was performed using Lympholyte Cell
Separation Media CL5015 (Cedarlane, Ontario, Canada). Mode values of PI
intensity of the live and dead cells are indicated with arrows. B: Cell
death rates in medium containing 0.1 or 0% serum. The results at 96 and
122 hours are relatively unclear because cell debris increased counting
error.
Additional file 4: Table S1. Raw data of the microarray analysis.
Additional file 5: Table S2. List of 117 genes with commonly altered
expression.
Additional file 6: Figure S4. A: Heat map (Blue color for low
expression and red color for high expression) and list for the expression
levels of the 117 genes. A detailed list of the 117 genes is also shown in
Additional file 5: Table S2. B: Pathway analysis for CD24, KIT and MS4A4.
Six genes chosen in Figure 5 were analyzed with Pathway analyzing
software, KeyMolnet (KMdata, Tokyo, Japan). Known interactions for
transmembrane proteins KIT, CD24 and MS4A4 (red-filled circles) were
found. Nuclear and cytoplasmic factors (blue-filled circles) are shown with
solid and dashed lines indicating actual binding and regulatory effects,
respectively.
Additional file 7: Table S3. GO term analysis performed with Ingenuity
Pathway analysis software (Qiagen).
Additional file 8: Figure S5. Expression of genes frequently altered in
AML. The representative expression of genes that are frequently altered
in AML patients was measured in KD, Vec (GER vector transformed) and
KD clones (22B11, 32H8, 3-4 and 3D1).
Additional file 9: Table S4. Primer sets used in this study.Abbreviations
AzdC: 5-aza-2′-deoxycytidine; AML: Acute myeloid leukemia; CML: Chronic
myeloid leukemia; CNA: Copy number alteration; DNMT: DNA
methyltransferase; KD: Knockdown; LSC: Leukemia stem cells; lncRNA: Long
noncoding RNA; PTGS: Post-transcriptional gene silencing; PI: Propidium
iodide; shRNA: Short hairpin RNA; RSV: Rous sarcoma virus;
TGS: Transcriptional gene silencing; TSA: Trichostatin A.
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